Poly Medicure’s board has approved the unaudited financial results for Q3 2025 (October-December) and the nine months ending December 31, 2025. Additionally, the Nomination & Remuneration Committee approved a grant of 2,000 stock options under the Employee Stock Option Scheme 2020 to eligible employees. The meeting, held on February 5, 2026, finalized these key decisions, signaling continued growth and employee investment.
Financial Performance Overview
The Board of Directors at Poly Medicure approved the unaudited financial results for Q3 2025 and the nine months ending December 31, 2025. Key highlights from the standalone results include:
- Revenue from operations for the nine months ended December 31, 2025: ₹121,944.99 lacs.
- Total income for the nine months ended December 31, 2025: ₹124,665.42 lacs.
- Profit before tax for the nine months ended December 31, 2025: ₹34,108.49 lacs, including an exceptional item (impact of labour codes) of ₹680.40 lacs.
- Profit after tax for the nine months ended December 31, 2025: ₹25,536.32 lacs.
For the consolidated results:
- Revenue from operations for the nine months ended December 31, 2025: ₹134,074.78 lacs.
- Total income for the nine months ended December 31, 2025: ₹144,307.35 lacs.
- Profit before tax for the nine months ended December 31, 2025: ₹34,224.90 lacs, including an exceptional item (impact of labour codes) of ₹680.40 lacs.
- Profit after tax for the nine months ended December 31, 2025: ₹25,568.90 lacs.
Employee Stock Options
The Nomination & Remuneration Committee approved the grant of 2,000 stock options under the Poly Medicure Limited Employee Stock Option Scheme 2020 to eligible employees. These options vest over a four-year term and can be exercised within three months from the relevant vesting date at a price of ₹100 per share.
Other Business Items
The Board meeting commenced at 12:45 PM and concluded at 02:35 PM on February 5, 2026.
Source: BSE
